Receptors, Peptide

"Receptors, Peptide" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Cell surface receptors that bind peptide messengers with high affinity and regulate intracellular signals which influence the behavior of cells.

Descriptor ID	D018000
MeSH Number(s)	D12.776.543.750.750
Concept/Terms	Receptors, Peptide Receptors, Peptide Peptide Receptors Peptide Receptor Receptor, Peptide Receptors, Peptides Peptides Receptors Peptide Hormone Receptors Peptide Hormone Receptors Hormone Receptors, Peptide Receptors, Peptide Hormone Peptide Hormone Receptor Hormone Receptor, Peptide Receptor, Peptide Hormone Receptors, Peptide Hormones Hormones Receptors, Peptide Peptide Hormones Receptors

Below are MeSH descriptors whose meaning is more general than "Receptors, Peptide".

Chemicals and Drugs [D]
Amino Acids, Peptides, and Proteins [D12]
Proteins [D12.776]
Membrane Proteins [D12.776.543]
Receptors, Cell Surface [D12.776.543.750]
Receptors, Peptide [D12.776.543.750.750]

Below are MeSH descriptors whose meaning is related to "Receptors, Peptide".

Below are MeSH descriptors whose meaning is more specific than "Receptors, Peptide".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Receptors, Peptide" by people in this website by year, and whether "Receptors, Peptide" was a major or minor topic of these publications.

Bar chart showing 53 publications over 14 distinct years, with a maximum of 10 publications in 2009

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2001	2	0	2
2002	3	1	4
2003	0	1	1
2005	4	2	6
2006	3	2	5
2007	2	1	3
2008	5	0	5
2009	9	1	10
2010	2	2	4
2011	3	1	4
2012	2	1	3
2013	1	0	1
2017	4	0	4
2023	0	1	1

Below are the most recent publications written about "Receptors, Peptide" by people in Profiles.

Van NT, Zhang K, Wigmore RM, Kennedy AI, DaSilva CR, Huang J, Ambelil M, Villagomez JH, O'Connor GJ, Longman RS, Cao M, Snook AE, Platten M, Kasenty G, Sigal LJ, Prendergast GC, Kim SV. Dietary L-Tryptophan consumption determines the number of colonic regulatory T cells and susceptibility to colitis via GPR15. Nat Commun. 2023 11 14; 14(1):7363.

View in: PubMed
Li P, Wuthrick E, Rappaport JA, Kraft C, Lin JE, Marszalowicz G, Snook AE, Zhan T, Hyslop TM, Waldman SA. GUCY2C Signaling Opposes the Acute Radiation-Induced GI Syndrome. Cancer Res. 2017 Sep 15; 77(18):5095-5106.

View in: PubMed
Aka AA, Rappaport JA, Pattison AM, Sato T, Snook AE, Waldman SA. Guanylate cyclase C as a target for prevention, detection, and therapy in colorectal cancer. Expert Rev Clin Pharmacol. 2017 May; 10(5):549-557.

View in: PubMed
Xiang B, Baybutt TR, Berman-Booty L, Magee MS, Waldman SA, Alexeev VY, Snook AE. Prime-Boost Immunization Eliminates Metastatic Colorectal Cancer by Producing High-Avidity Effector CD8+ T Cells. J Immunol. 2017 May 01; 198(9):3507-3514.

View in: PubMed
Youssefian L, Vahidnezhad H, Aghighi Y, Ziaee V, Zeinali S, Abiri M, Uitto J. Hyaline Fibromatosis Syndrome: A Novel Mutation and Recurrent Founder Mutation in the CMG2/ANTXR2 Gene. Acta Derm Venereol. 2017 01 04; 97(1):108-109.

View in: PubMed
Kim SV, Xiang WV, Kwak C, Yang Y, Lin XW, Ota M, Sarpel U, Rifkin DB, Xu R, Littman DR. GPR15-mediated homing controls immune homeostasis in the large intestine mucosa. Science. 2013 Jun 21; 340(6139):1456-9.

View in: PubMed
Gong JP, Schulz S, Hyslop T, Waldman SA. GUCY2C molecular staging personalizes colorectal cancer patient management. Biomark Med. 2012 Jun; 6(3):339-48.

View in: PubMed
Mejia A, Schulz S, Hyslop T, Weinberg DS, Waldman SA. Molecular staging individualizing cancer management. J Surg Oncol. 2012 Apr 1; 105(5):468-74.

View in: PubMed
Lin JE, Snook AE, Li P, Stoecker BA, Kim GW, Magee MS, Garcia AV, Valentino MA, Hyslop T, Schulz S, Waldman SA. GUCY2C opposes systemic genotoxic tumorigenesis by regulating AKT-dependent intestinal barrier integrity. PLoS One. 2012; 7(2):e31686.

View in: PubMed
Snook AE, Magee MS, Waldman SA. GUCY2C-targeted cancer immunotherapy: past, present and future. Immunol Res. 2011 Dec; 51(2-3):161-9.

View in: PubMed

People

Explore

Similar Concepts

Top Journals

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement